bs are potent inhibitors of epithelial cell proliferation. However, in established carcinomas, autocrine/paracrine TGF-b interactions can enhance tumor cell viability and progression. Thus, we studied the effect of a soluble Fc:TGF-b type II receptor fusion protein (Fc:TbRII) on transgenic and transplantable models of breast cancer metastases. Systemic administration of Fc:TbRII did not alter primary mammary tumor latency in MMTVPolyomavirus middle T antigen transgenic mice. However, Fc:TbRII increased apoptosis in primary tumors, while reducing tumor cell motility, intravasation, and lung metastases. These effects correlated with inhibition of Akt activity and FKHRL1 phosphorylation. Fc:TbRII also inhibited metastases from transplanted 4T1 and EMT-6 mammary tumors in syngeneic BALB/c mice. Tumor microvessel density in a mouse dorsal skin window chamber was unaffected by Fc:TbRII. Therefore, blockade of TGF-b signaling may reduce tumor cell viability and migratory potential and represents a testable therapeutic approach against metastatic carcinomas.
Introduction
Tumor metastases are the result of a complex process that involves cellular migration, tumor vascularization, interactions with the microenvironment, intravasation into blood or lymphatic vessels, and cell survival at distant sites (1) . TGF-β is a multifunctional cytokine involved in several of these processes (2, 3) . The role of TGF-β in the biology of epithelial cells is complex. TGF-β potently inhibits the proliferation of epithelial cells (2) . Transgenic mice that overexpress active TGF-β1 in mammary epithelium exhibit hypoplastic mammary glands that are resistant to oncogene-or carcinogen-induced mammary cancers (4) (5) (6) . In a mouse skin model of chemical carcinogenesis, expression of TGF-β1 in keratinocytes suppresses the formation of benign skin tumors. Once tumors develop, however, TGF-β1 enhances tumor progression to a highly invasive spindle cell phenotype (7) . Ha-Ras-induced mammary tumor cells secrete high levels of TGF-β and display highly invasive characteristics in vitro and in vivo (8) . Introduction of dominant negative TGF-β type II receptors (TβRII) into these cells retards primary tumor and metastases formation and prevents epithelial-to-mesencymal transition (EMT) (9) . It appears, then, that many epithelial tumors escape growth inhibition by TGF-β, and TGF-β secretion by cancer and/or stromal cells may contribute to late tumor progression. Tumor TGF-β secretion may also indirectly favor metastatic progression by increasing extracellular matrix production/degradation, inducing tumor vascularization, and inhibiting effector mechanisms of immune surveillance (3, 10) .
We have investigated the effect of TGF-β on breast cancer metastasis using a soluble chimeric protein composed of the extracellular domain of the TβRII and the Fc portion of the murine IgG 1 heavy chain (Fc:TβRII) (11) . This chimera interferes with TGF-β binding to endogenous TGF-β receptors and has been shown to block TGF-β-induced fibrosis in vivo (12) .
immunoblot analysis using an anti-mouse IgG 2A -HRP (Southern Biotechnology Associates, Birmingham, Alabama, USA) against an Fc:TβRII standard curve (3.3-66 nM) .
Histological analyses. Paraffin sections (5 µm) were stained with hematoxylin and eosin (Sigma-Aldrich, St. Louis, Missouri, USA). For immunohistochemistry, sections were treated as described (14) , using Ab's against CD31 (1:100; Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) or PyV mT antigen (pAb 701 [see ref . 15 ]; 1:50; provided by Steven Dilworth, Imperial Cancer Research Fund, London, United Kingdom). Immunohistochemical detection of bromodeoxyuridine (BrdU) incorporation and apoptosis was performed as described (16) . Immunocytochemistry for Smad2, FKHRL1, vimentin, or β-catenin used Smad2 (1:100; Santa Cruz Biotechnology Inc.), FKHRL1 (1:100, Upstate Biotechnology Inc., Lake Placid, New York USA), vimentin (1:100; Santa Cruz Biotechnology Inc.), or β-catenin Ab's (Signal Transduction Laboratories, Lexington, Kentucky, USA), and Cy3-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, Pennsylvania, USA).
Primary mammary tumor cell isolation and motility/invasion assays. Tumors from 110-day-old mice were digested (37°C, 4 hours) in 3 mg/ml collagenase A (SigmaAldrich), washed (PBS/10% FBS), and plated in DMEM:F12 (50:50; Life Technologies Inc., Carlsbad, California, USA), 5 ng/ml EGF, 5 ng/ml 17-β estradiol, 5 ng/ml progesterone, and 50 ng/ml insulin (all from Sigma-Aldrich). For wound closure assays, primary mammary tumor cells (PMTCs) were grown to confluence, treated with 80 pM (2 ng/ml) TGF-β1, 20 nM Fc:TβRII, or both, and wounded with a sterile circular rubber eraser (1 cm diameter). Cells were photographed at 0, 8, 16, 24, and 48 hours after wounding. The area of the circle enclosed by cells was determined using BioQuant (R&M Biometrics, Nashville, Tennessee, USA) software. Experiments were conducted with and without mitomycin C (1 µg/ml; Sigma-Aldrich). For invasion assays, PMTCs, 4T1, or EMT6 cells (10 4 each) were seeded in the upper chamber of transwells fitted with Matrigel-coated 8-µM poresize polycarbonate filters (Corning Life Sciences, Acton, Massachusetts, USA). Lower chambers contained 2.5% serum with or without 20 nM Fc:TβRII. After 24 hours, cells were scraped from upper filter surfaces, and the cells on the lower surfaces were stained and counted.
Western blot analyses. Total protein (20 µg) was harvested and Western blot analysis performed as described previously (17) using the following Ab's: Shc, p85, Src, VEGF, and CD31 (all from Santa Cruz Biotechnology Inc.); Akt and Ser 473 P-Akt (Transduction Laboratories, Lexington, Kentucky, USA); FKHRL1 and phospho-FKHRL1 (Upstate Biotechnology Inc.). Densitometric analysis was performed using ImageQuant software (Molecular Dynamics ImageQuant, Sunnyvale, California, USA).
125 I-TGF-β1 labeling. PMTCs were affinity labeled with 100 pM 125 I-TGF-β1 (NEN Life Science Products Inc., Boston, Massachusetts, USA) as described (18) . In some cases, cross-linked cell lysates were precipitated with Ab (1 µg) against type I (V22) or type II (C16) TGF-β receptors (both from Santa Cruz Biotechnology Inc.). All samples were fractionated using 3-12% gradient SDS-PAGE, followed by autoradiography.
TGF-β reporter assays. PMTCs (0.5 × 10 6 ) were transfected with p3TP-Lux (2 µg) as described (19) . After 48 hours, cells were treated for 6 hours with 80 pM TGF-β1, 20 nM Fc:TβRII, or both. Luciferase activity was determined using the Dual Luciferase Assay system (Promega Corp., Madison, Wisconsin, USA).
Measurement of secreted TGF-β. PMTCs (2 × 10 6 ) or primary mammary epithelial cells from wild-type mice were cultured for 24 hours in 3 ml of serum-free PMTC media. Conditioned medium was collected, concentrated to 0.5 ml, and TGF-β1 levels in media were determined using a TGF-β1 ELISA (R&D Systems Inc., Minneapolis, Minnesota, USA).
Intravasation assay. Circulating tumor cells in 110-dayold PyV mT mice were quantified as described in Wyckoff et al. (20) . One milliliter of blood was collected by heart puncture and centrifuged (1200 g, 4°C, 5 minutes). The serum/buffy-coat layers were plated in 1 ml DMEM:F12 (50:50)/10% FBS. After 24 hours, the plates were washed with PBS to remove erythrocytes and nonadherent cells, and fresh DMEM:F12/10% FBS was replenished. After 7 days, colonies were stained with hematoxylin and counted.
Matrix metalloproteinase activity. Mouse tumors were harvested in 25 mM Tris-HCl, pH 7.8, 0.5 M NaCl, 1% NP-40, and EDTA-free protease inhibitor cocktail (Roche Diagnostics GmbH, Mannheim, Germany). Fifty micrograms of protein was analyzed for matrix metalloprotease-2/matrix metalloproteinase-9 (MMP-2/ MMP-9) combined activity using the MMP Activity Assay Kit (Chemicon International Inc., Temecula, California, USA). The relative MMP activity per sample was compared with the MMP activity in 0.2 µg of recombinant MMP-2 (Chemicon International Inc.).
Transplants/metastases of 4T1 and EMT6 tumor cells. 4T1 or EMT6 cells (0.5 × 10 5 ) were injected into number 4 mammary glands of BALB/c virgin female mice. Mice were treated with Fc:TβRII as described above. After 10 days, primary tumors were resected. Lungs were harvested 8 weeks later, and surface metastases were counted.
Dorsal skin window assay. Window chambers were prepared in dorsal skin folds of female BALB/c mice as described (21) . 4T1-green fluorescent protein (4T1-GFP) (22) cells (1,000 cells) were implanted in the chambers along with 1 mm 3 slow-release hydron pellets impregnated with Fc:TβRII (1 µg), normal mouse IgG (1 µg), or PBS. Growth of 4T1-GFP cells and vessels was observed within the window from days 0-15 using fluorescence and bright-field microscopy. On day 15, 100 µl of rhodamine-conjugated dextran (1 mg/ml) was injected intravenously to label functional vessels. Fluorescence was quantified using Scion Image software. Figure 1b ). Mammary glands from wildtype FVB mice treated with Fc:TβRII also displayed increased ductal secretions, a result reminiscent of the precocious alveolar differentiation exhibited by transgenic mice expressing a dominant negative TβRII in mammary epithelium (23, 24) . At 110 days, mice treated with Fc:TβRII displayed tumors in all 10 mammary glands, as did IgG-treated mice. Total tumor weight for mice treated with Fc:TβRII was 16.3 ± 3.2 g, compared with 17.9 ± 2.4 g for mice treated with IgG (unpaired Student t test, P = 0.11). Immunoblot analysis of 1:100 dilutions of mouse serum detected approximate Fc:TβRII levels between 6.6 and 66 nM (data not shown). Increased apoptosis was observed in tumors from 10-week-old mice treated with Fc:TβRII (2.4%) compared with controls (0.9%; P = 0.024; n = 6 per group; unpaired Student t test), as determined by TUNEL analysis (Figure 1c) . However, treatment with Fc:TβRII did not alter the rate of tumor cell proliferation as assessed by BrdU incorporation (P = 0.08; n = 6 per group). These results were confirmed in purified PMTCs harvested from 110-day-old MMTVPyV mT mice. BrdU incorporation in PMTCs in culture was not altered by TGF-β1 (14.3% ± 1.07%), by Fc:TβRII (15.57% ± 1.52%), or by a combination of both (15.62% ± 1.52%), as compared with PMTCs treated with IgG (15.1% ± 1.15%).
Results

Soluble
Because mammary tumorigenesis induced by the PyV mT antigen has been shown to depend on the Shc, phosphatidylinositol-3 kinase (PI3K), and Src signaling pathways (25, 26) , we investigated whether Fc:TβRII interfered with these mechanisms in the primary tumors. Tumor contents of Shc and p85, the regulatory subunit of PI3K, were unaffected by Fc:TβRII (Figure 1d ). Src expression, detected by immunoblot (Figure 2b) , as well as transcription from the TGF-β-responsive reporter 3TP-Lux (Figure 2c ). Both basal and TGF-β-induced reporter activity were blocked by Fc:TβRII (Figure 2c ). These results suggest that TGF-β receptor-mediated signaling is intact in PyV mT mouse-derived cells. In addition, PMTCs synthesize and secrete close to 1 ng/ml/24 h of TGF-β1 (Figure 2d) . Fc:TβRII impaired ligand-induced and basal motility of PMTCs (Figure 2e ). The rate of wound closure was the same in the presence or absence of mitomycin C, suggesting that these effects were independent of cell proliferation (not shown). In transwell invasion assays, PMTCs, 4T1, and EMT6 BALB/c mammary tumor cells migrated through extracellular matrix (Matrigel) to the opposite sides of filters. In each case, tumor cell migration was impaired by Fc:TβRII ( Figure  2f ). Cultured PMTCs treated with TGF-β1 and Fc:TβRII or with TGF-β1 alone were analyzed for expression of either β-catenin or vimentin using immunocytochemistry (Figure 2g) . PMTCs treated with TGF-β1 and Fc:TβRII together displayed abundant β-catenin expression that was localized to the cell membranes. However, β-catenin expression was downregulated in PMTCs treated with TGF-β1. Vimentin expression, a marker of epithelial-to-mesenchymal transition, was observed in TGF-β1-treated PMTCs, but was not observed in PMTCs treated with Fc:TβRII and TGF-β together.
Blockade of TGF-β with Fc:TβRII reduces mammary tumor cell intravasation and lung metastases. At 110 days, lungs from transgenic mice were collected and examined for surface metastases. Lung surface metastases were observed in control mice and mice treated with Fc:TβRII. However, Fc:TβRII-treated mice displayed significantly lower wet lung weight (Table 1) and tenfold fewer lung surface metastases than controls (Figure 3a) . All lung metastases expressed the MMTV-PyV mT transgene product as measured by immunohistochemistry (Figure 3a) . Tumor cell intravasation was measured by collecting blood via atrial puncture and culturing the serum and buffy-coat layers (20) . After 1 week, we determined the number of epithelial colonies ( Figure  3b ). Blood from wild-type mice produced no colonies. However, blood from control and Fc:TβRII-treated mice grew an average of 71.3 ± 8.3 and 11.0 ± 2.6 colonies per mouse, respectively (n = 6 per group; P < 0.009; unpaired student t test). Although we cannot rule out the possibility that Fc:TβRII affected the survival of circulating tumor cells, these results suggest that Fc:TβRII might interfere with the ability of tumor cells to migrate from the primary tumor and intravasate. Since TGF-β can also induce the expression of MMPs (10), we examined MMP activity in mammary tumor extracts. When normalized for protein content, the relative combined MMP-2 and MMP-9 activities were reduced in lysates prepared from Fc:TβRII-treated versus control tumors ( Table 1) . The relative levels of MMP activity were measured in extracts prepared from purified PMTCs treated in culture with Fc:TβRII or with control IgG. We found decreased MMP activity in Fc:TβRII-treated PMTC lysates compared with IgG-treated PMTC lysates, consistent with the hypothesis that Fc:TβRII may impair MMP activity in tumor cells.
To confirm that the antimetastatic effect of Fc:TβRII was not limited to PyV mT mice, we studied the effect of Fc:TβRII on 4T1 and EMT6 mammary tumor cell metastases. These transplantable mouse The number of colonies derived from circulating blood of 70-day-old wild-type or PyV mT mice was quantified (see Figure 3b) . Values shown are the average number of colonies derived per mouse, n = 6 per condition. The average number of macroscopic surface lung metastases per mouse was determined and counted by two different individuals (R.S. Muraoka and E. Easterly) in a blinded fashion; n >10 per condition. Wet lung weight was determined at time of death; n >10 per condition. Relative combined activity of MMP-2 and MMP-9 in mammary tissue extracts or cell lysates of purified PMTCs was determined using ELISA-based detection of MMP cleavage products (see Methods displayed no differences in the number of CD31-positive tumor vessels compared with controls (not shown).
Dorsal skin window assays (21) were performed to assess early stages of angiogenesis. 4T1 tumor cells expressing GFP (22) were implanted into a dorsal window chamber. A hydron pellet impregnated with Fc:TβRII, PBS, or normal mouse IgG was implanted in the chamber. 4T1 tumor formation and vascularization were monitored over a 15-day period. At day 5, the 4T1-GFP cells in the window chamber containing a control hydron pellet were present at a higher density than those in the presence of an Fc:TβRII pellet. Upon higher magnification, Fc:TβRII-treated cells were rounded compared with the spindle-shaped 4T1-GFP cells in control chambers. At day 10, Fc:TβRII-treated cells remained as rounded, single cells (Figure 5c ). At day 14, mice were administered rhodamine-dextran intravenously to visualize vascularization of tumors. There were no differences in vascularity of control versus Fc:TβRII-treated 4T1-GFP tumors as measured by rhodamine-fluorescent pixels. However, tumor density determined by the number of GFP-fluorescent pixels was decreased in the Fc:TβRII-treated mice ( Figure 5d and Table 2 ), suggesting that Fc:TβRII may have an effect on tumor cells independent of any detectable effect on endothelial cell recruitment and/or new vessel formation.
Discussion
Blockade of TGF-β signaling with soluble Fc:TβRII inhibited the formation of distant metastases in three experimental models of breast cancer. Although responsive to exogenous TGF-β (Figure 2) , inhibition of TGF-β signaling using Fc:TβRII did not alter cellular proliferation in the tumor cells used in this study, neither in vitro nor in vivo (Figure 1c) , suggesting that the antimetastatic effects of Fc:TβRII in vivo were independent of tumor cell proliferation. However, treatment with Fc:TβRII inhibited tumor cell motility (Figure 2 ) and intravasation (Figure 3 ), inhibited MMP activity in tumors (Table 1) , and increased cancer cell apoptosis in situ (Figure 1 ). These data suggest that TGF-β signaling contributes to metastasis (33) and that Fc:TβRII (or other mechanisms of systemic inhibition of TGF-β1 signaling) may be an effective treatment for the prevention of tumor cell metastasis. These data are consistent with studies in which inactivating mutations in the TβRII gene in colon cancers correlate with a low invasive potential; introduction of exogenous TβRII into these colon cancer cells increased tumor cell invasion (9) . Approximately 90% of colon cancers with microsatellite instability have inactivating mutations of TβRII (34) , which correlates with longer patient survival (35) , implying that loss of TGF-β signaling may limit systemic metastases.
Mammary tumors from mice treated with Fc:TβRII displayed a higher rate of apoptosis than that observed for control-treated tumors. Interestingly, we found that Fc:TβRII inhibited phosphorylation of Akt on serine 473. Phosphorylation on serine 473 is required for maximal Akt kinase activity resulting in subsequent phosphorylation of multiple downstream targets of Akt, such as p21, p27, GSK3β, IKKα, and FKHRL1. Phosphorylation of FKHRL1 by Akt results in the cytoplasmic retention (i.e., nuclear exclusion) of FKHRL1, thus preventing FKHRL1-induced transcription of death-associated genes. Therefore, inhibition of Akt might conceivably result in enhanced nuclear localization of FKHRL1 and increased cell death. The data reported herein suggest that, by inhibiting the phosphorylation/activation of Akt, Fc:TβRII treatment resulted in increased nuclear localization of FKHRL1. This correlated with an increase in the number of apoptotic nuclei in situ in tumors treated with Fc:TβRII. These data are consistent with reports published previously demonstrating the reported induction of PI3K by TGF-β (42). TGF-β-neutralizing Ab's are known to inhibit phosphorylation of Akt at serine 473 in 4T1 and EMT6 cells (19) . More recently, it was shown that TGF-β enhances epithelial cell survival via Akt-induced phosphorylation and nuclear exclusion of FKHRL1 (30) . Therefore, inhibition of TGF-β-induced AKT activity by Fc:TβRII may enhance tumor cell death and limit metastatic progression.
The data presented cannot rule out the possibility that Fc:TβRII-mediated blockade of TGF-β signaling in immune effector cells might lead to eradication of tumor, as demonstrated recently in mice expressing dominant negative TβRII in CD4 + and CD8 + T cells (36) . It is difficult to compare the results presented herein with the powerful results reported by Gorelick and Flavell (36) , who used a highly aggressive, poorly immunogenic, transplantable model of melanoma, while our studies examined the endogenous formation of breast tumors from preneoplastic mammary epithelium. This difference may present differences in the mechanisms by which the immune system recognize tumor cells. Additionally, TGF-β may have different effects on tumor progression at different stages of tumorigenesis. TGF-β is thought to act as a tumor suppressor early in tumorigenesis, perhaps by inhibiting cell proliferation. Later in tumor progression, however, TGF-β may not inhibit tumor cell proliferation and may actually enhance tumor cell invasion and the tumor microenvironment, while inhibiting tumoricidal activity of the immune system, thus enhancing tumor progression. It is conceivable that Fc:TβRII would interfere with each of these effects of TGF-β on tumor progression. Nonetheless, the studies showing inhibition of TGF-β signaling in T cells, taken together with data presented herein, demonstrate a beneficial effect in tumor metastasis prevention by inhibition of TGF-β signaling.
Our studies suggest that inhibition of TGF-β signaling using Fc:TβRII may not interfere with tumor angiogenesis in vivo. This finding is in contrast to other studies using TGF-β inhibitors (10, 32) . TGF-β is predominantly involved in smooth muscle cell differentiation and migration leading to pericyte recruitment and vessel stabilization (37) . However, the majority of intratumor neovessels lack periendothelial smooth muscle cells (38) , potentially explaining our inability to detect a reduction of in situ vascular density in endogenously arising tumors and in dorsal skin window chambers.
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The The density of 4T1 tumor cells in dorsal skin window chambers was quantified at the indicated time points as the average number of GFP-generated fluorescent pixels per ×20 field (see Figure 5 , c and d) using Scion Image software, n = 6 per condition. The vascular density of 4T1 tumors in dorsal skin window chambers was quantified as the average number of rhodamine-generated fluorescent pixels per ×20 field (see Figure 5d ) using Scion Image software, n = 6 per condition.
In summary, the mechanisms by which TGF-β can promote late stages of tumor progression represent testable molecular targets for novel interventions like Fc:TβRII. Our results suggest that inhibition of TGF-β signaling results in decreased metastasis of mammary tumors by impairing invasion, migration, and cellular survival. The lack of any obvious toxicity in mice treated with Fc:TβRII for 12 weeks suggests that Fc:TβRII or other inhibitors of the TGF-β signaling pathway may prove to be powerful antimetastatic therapies.
